Update on the classification of low-grade gliomas: the relevance of molecular diagnostics

Prof. van den Bent discusses how molecular analysis is helping us understand the clinical behavior of gliomas with low-grade histology.

Dr van den Bent is / was a consultant / advisor for Cathera, Inc.; Bayer AG; Agios Pharmaceuticals Inc.; Nerviano Medical Sciences; Genenta Science; Karyopharm Therapeutics and Amgen Inc.